Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | Director | May 01, 2023 | May 03, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
VERTEX PHARMACEUTICALS INC / MA
Report date May 01, 2023 · Filed May 03, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $342.73 · Expires 2033-04-30 | Direct | 3,481 |
Reported balance
After 2023-05-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-05-01 · Grant · Acquired 3,481 · Balance 3,481 F1: Fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 28, 2020 Filed Apr 29, 2020 20:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,125 | $0.00 Strike: $57.27 | $0.00 |
DisclosureSEC source: 0001209191-20-026153 · doc4.xml · derivative · entry 9 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,125 shares Expires 2022-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: Fully vested. Read SEC document |
| April 28, 2020 Filed Apr 29, 2020 20:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 116 | $261.80 | $30,368.80 |
DisclosureSEC source: 0001209191-20-026153 · doc4.xml · nonDerivative · entry 8 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,875 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F9 · price: Open market sales reported on this line occurred at a weighted average price of $261.80 (range $261.58 to $262.00). Read SEC document |
| April 28, 2020 Filed Apr 29, 2020 20:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 180 | $260.53 | $46,895.40 |
DisclosureSEC source: 0001209191-20-026153 · doc4.xml · nonDerivative · entry 7 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,991 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F8 · price: Open market sales reported on this line occurred at a weighted average price of $260.53 (range $260.32 to $260.94). Read SEC document |
| April 28, 2020 Filed Apr 29, 2020 20:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 120 | $259.61 | $31,153.20 |
DisclosureSEC source: 0001209191-20-026153 · doc4.xml · nonDerivative · entry 6 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,171 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $259.61 (range $259.28 to $259.94). Read SEC document |
| April 28, 2020 Filed Apr 29, 2020 20:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 120 | $258.53 | $31,023.60 |
DisclosureSEC source: 0001209191-20-026153 · doc4.xml · nonDerivative · entry 5 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,291 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $258.53 (range $258.13 to $258.92). Read SEC document |
| April 28, 2020 Filed Apr 29, 2020 20:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 149 | $257.20 | $38,322.80 |
DisclosureSEC source: 0001209191-20-026153 · doc4.xml · nonDerivative · entry 4 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,411 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $257.20 (range $256.87 to $257.37). Read SEC document |
| April 28, 2020 Filed Apr 29, 2020 20:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 240 | $255.79 | $61,389.60 |
DisclosureSEC source: 0001209191-20-026153 · doc4.xml · nonDerivative · entry 3 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,560 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $255.79 (range $255.40 to $256.14). Read SEC document |
| April 28, 2020 Filed Apr 29, 2020 20:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 200 | $254.81 | $50,962.00 |
DisclosureSEC source: 0001209191-20-026153 · doc4.xml · nonDerivative · entry 2 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,800 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $254.81 (range $254.32 to $255.26). F3 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| April 28, 2020 Filed Apr 29, 2020 20:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,125 | $57.27 | $64,428.75 |
DisclosureSEC source: 0001209191-20-026153 · doc4.xml · nonDerivative · entry 1 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 27, 2020 Filed Apr 28, 2020 20:23 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $57.27 | $0.00 |
DisclosureSEC source: 0001209191-20-025937 · doc4.xml · derivative · entry 13 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,125 Underlying: Common Stock · 2,000 shares Expires 2022-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: Fully vested. Read SEC document |
| April 27, 2020 Filed Apr 28, 2020 20:23 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 100 | $273.44 | $27,344.00 |
DisclosureSEC source: 0001209191-20-025937 · doc4.xml · nonDerivative · entry 11 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,875 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. Read SEC document |
| April 27, 2020 Filed Apr 28, 2020 20:23 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 200 | $272.51 | $54,502.00 |
DisclosureSEC source: 0001209191-20-025937 · doc4.xml · nonDerivative · entry 10 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,975 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F10 · price: Open market sales reported on this line occurred at a weighted average price of $272.51 (range $272.31 to $272.71). Read SEC document |
| April 27, 2020 Filed Apr 28, 2020 20:23 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,113 | $271.56 | $302,246.28 |
DisclosureSEC source: 0001209191-20-025937 · doc4.xml · nonDerivative · entry 9 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,175 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F9 · price: Open market sales reported on this line occurred at a weighted average price of $271.56 (range $271.12 to $272.00). Read SEC document |
| April 27, 2020 Filed Apr 28, 2020 20:23 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 394 | $270.37 | $106,525.78 |
DisclosureSEC source: 0001209191-20-025937 · doc4.xml · nonDerivative · entry 8 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,288 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F8 · price: Open market sales reported on this line occurred at a weighted average price of $270.37 (range $270.08 to $270.78). Read SEC document |
| April 27, 2020 Filed Apr 28, 2020 20:23 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 193 | $268.40 | $51,801.20 |
DisclosureSEC source: 0001209191-20-025937 · doc4.xml · nonDerivative · entry 7 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,682 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $268.40 (range $268.05 to $268.77). Read SEC document |
| April 27, 2020 Filed Apr 28, 2020 20:23 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 2,000 | $57.27 | $114,540.00 |
DisclosureSEC source: 0001209191-20-025937 · doc4.xml · nonDerivative · entry 6 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,875 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 24, 2020 Filed Apr 28, 2020 20:23 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $57.27 | $0.00 |
DisclosureSEC source: 0001209191-20-025937 · doc4.xml · derivative · entry 12 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,125 Underlying: Common Stock · 2,000 shares Expires 2022-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: Fully vested. Read SEC document |
| April 24, 2020 Filed Apr 28, 2020 20:23 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 120 | $270.30 | $32,436.00 |
DisclosureSEC source: 0001209191-20-025937 · doc4.xml · nonDerivative · entry 5 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,875 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $270.30 (range $270.05 to $270.33). Read SEC document |
| April 24, 2020 Filed Apr 28, 2020 20:23 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 400 | $269.28 | $107,712.00 |
DisclosureSEC source: 0001209191-20-025937 · doc4.xml · nonDerivative · entry 4 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,995 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $269.28 (range $269.00 to $269.64). Read SEC document |
| April 24, 2020 Filed Apr 28, 2020 20:23 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 590 | $268.31 | $158,302.90 |
DisclosureSEC source: 0001209191-20-025937 · doc4.xml · nonDerivative · entry 3 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,395 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $268.31 (range $267.94 to $268.77). Read SEC document |
| April 24, 2020 Filed Apr 28, 2020 20:23 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 890 | $267.23 | $237,834.70 |
DisclosureSEC source: 0001209191-20-025937 · doc4.xml · nonDerivative · entry 2 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,985 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $267.23 (range $266.72 to $267.71). F3 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| April 24, 2020 Filed Apr 28, 2020 20:23 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 2,000 | $57.27 | $114,540.00 |
DisclosureSEC source: 0001209191-20-025937 · doc4.xml · nonDerivative · entry 1 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,875 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 23, 2020 Filed Apr 24, 2020 20:17 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $57.27 | $0.00 |
DisclosureSEC source: 0001209191-20-025596 · doc4.xml · derivative · entry 17 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,125 Underlying: Common Stock · 2,000 shares Expires 2022-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F14 · derivative.exercise_date: Fully vested. Read SEC document |
| April 23, 2020 Filed Apr 24, 2020 20:17 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 47 | $276.45 | $12,993.15 |
DisclosureSEC source: 0001209191-20-025596 · doc4.xml · nonDerivative · entry 15 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,875 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. Read SEC document |
| April 23, 2020 Filed Apr 24, 2020 20:17 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 600 | $275.90 | $165,540.00 |
DisclosureSEC source: 0001209191-20-025596 · doc4.xml · nonDerivative · entry 14 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,922 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F13 · price: Open market sales reported on this line occurred at a weighted average price of $275.90 (range $275.44 to $276.40). Read SEC document |
| April 23, 2020 Filed Apr 24, 2020 20:17 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 400 | $274.23 | $109,692.00 |
DisclosureSEC source: 0001209191-20-025596 · doc4.xml · nonDerivative · entry 13 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,522 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F12 · price: Open market sales reported on this line occurred at a weighted average price of $274.23 (range $273.69 to $274.66). Read SEC document |
| April 23, 2020 Filed Apr 24, 2020 20:17 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 100 | $272.55 | $27,255.00 |
DisclosureSEC source: 0001209191-20-025596 · doc4.xml · nonDerivative · entry 12 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,922 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. Read SEC document |
| April 23, 2020 Filed Apr 24, 2020 20:17 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 300 | $271.03 | $81,309.00 |
DisclosureSEC source: 0001209191-20-025596 · doc4.xml · nonDerivative · entry 11 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,022 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F11 · price: Open market sales reported on this line occurred at a weighted average price of $271.03 (range $270.69 to $271.65). Read SEC document |
| April 23, 2020 Filed Apr 24, 2020 20:17 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 200 | $269.23 | $53,846.00 |
DisclosureSEC source: 0001209191-20-025596 · doc4.xml · nonDerivative · entry 10 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,322 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F10 · price: Open market sales reported on this line occurred at a weighted average price of $269.23 (range $268.80 to $269.66). Read SEC document |
| April 23, 2020 Filed Apr 24, 2020 20:17 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 353 | $267.47 | $94,416.91 |
DisclosureSEC source: 0001209191-20-025596 · doc4.xml · nonDerivative · entry 9 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,522 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F9 · price: Open market sales reported on this line occurred at a weighted average price of $267.47 (range $267.04 to $267.97). Read SEC document |
| April 23, 2020 Filed Apr 24, 2020 20:17 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 2,000 | $57.27 | $114,540.00 |
DisclosureSEC source: 0001209191-20-025596 · doc4.xml · nonDerivative · entry 8 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,875 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 22, 2020 Filed Apr 24, 2020 20:17 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $57.27 | $0.00 |
DisclosureSEC source: 0001209191-20-025596 · doc4.xml · derivative · entry 16 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,125 Underlying: Common Stock · 2,000 shares Expires 2022-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F14 · derivative.exercise_date: Fully vested. Read SEC document |
| April 22, 2020 Filed Apr 24, 2020 20:17 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 369 | $270.54 | $99,829.26 |
DisclosureSEC source: 0001209191-20-025596 · doc4.xml · nonDerivative · entry 7 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,875 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F8 · price: Open market sales reported on this line occurred at a weighted average price of $270.54 (range $270.28 to $270.91). Read SEC document |
| April 22, 2020 Filed Apr 24, 2020 20:17 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 300 | $269.47 | $80,841.00 |
DisclosureSEC source: 0001209191-20-025596 · doc4.xml · nonDerivative · entry 6 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,244 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $269.47 (range $269.23 to $269.60). Read SEC document |
| April 22, 2020 Filed Apr 24, 2020 20:17 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 224 | $268.48 | $60,139.52 |
DisclosureSEC source: 0001209191-20-025596 · doc4.xml · nonDerivative · entry 5 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,544 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $268.48 (range $268.15 to $269.10). Read SEC document |
| April 22, 2020 Filed Apr 24, 2020 20:17 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 507 | $267.34 | $135,541.38 |
DisclosureSEC source: 0001209191-20-025596 · doc4.xml · nonDerivative · entry 4 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,768 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $267.34 (range $267.09 to $267.67). Read SEC document |
| April 22, 2020 Filed Apr 24, 2020 20:17 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 300 | $266.18 | $79,854.00 |
DisclosureSEC source: 0001209191-20-025596 · doc4.xml · nonDerivative · entry 3 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,275 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $266.18 (range $265.84 to $266.83). Read SEC document |
| April 22, 2020 Filed Apr 24, 2020 20:17 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 300 | $265.16 | $79,548.00 |
DisclosureSEC source: 0001209191-20-025596 · doc4.xml · nonDerivative · entry 2 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,575 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $265.16 (range $264.63 to $265.55). F3 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| April 22, 2020 Filed Apr 24, 2020 20:17 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 2,000 | $57.27 | $114,540.00 |
DisclosureSEC source: 0001209191-20-025596 · doc4.xml · nonDerivative · entry 1 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,875 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 21, 2020 Filed Apr 22, 2020 20:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $57.27 | $0.00 |
DisclosureSEC source: 0001209191-20-025342 · doc4.xml · derivative · entry 15 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,125 Underlying: Common Stock · 2,000 shares Expires 2022-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: Fully vested. Read SEC document |
| April 21, 2020 Filed Apr 22, 2020 20:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 100 | $272.63 | $27,263.00 |
DisclosureSEC source: 0001209191-20-025342 · doc4.xml · nonDerivative · entry 13 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,875 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. Read SEC document |
| April 21, 2020 Filed Apr 22, 2020 20:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 300 | $271.38 | $81,414.00 |
DisclosureSEC source: 0001209191-20-025342 · doc4.xml · nonDerivative · entry 12 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,975 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F10 · price: Open market sales reported on this line occurred at a weighted average price of $271.38 (range $271.12 to $271.69). Read SEC document |
| April 21, 2020 Filed Apr 22, 2020 20:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 100 | $268.50 | $26,850.00 |
DisclosureSEC source: 0001209191-20-025342 · doc4.xml · nonDerivative · entry 11 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,275 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. Read SEC document |
| April 21, 2020 Filed Apr 22, 2020 20:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 403 | $267.15 | $107,661.45 |
DisclosureSEC source: 0001209191-20-025342 · doc4.xml · nonDerivative · entry 10 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,375 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F9 · price: Open market sales reported on this line occurred at a weighted average price of $267.15 (range $266.85 to $267.47). Read SEC document |
| April 21, 2020 Filed Apr 22, 2020 20:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 300 | $265.88 | $79,764.00 |
DisclosureSEC source: 0001209191-20-025342 · doc4.xml · nonDerivative · entry 9 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,778 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F8 · price: Open market sales reported on this line occurred at a weighted average price of $265.88 (range $265.45 to $266.33). Read SEC document |
| April 21, 2020 Filed Apr 22, 2020 20:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 500 | $264.80 | $132,400.00 |
DisclosureSEC source: 0001209191-20-025342 · doc4.xml · nonDerivative · entry 8 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,078 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $264.80 (range $264.33 to $265.14). Read SEC document |
| April 21, 2020 Filed Apr 22, 2020 20:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 297 | $263.20 | $78,170.40 |
DisclosureSEC source: 0001209191-20-025342 · doc4.xml · nonDerivative · entry 7 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,578 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $263.20 (range $262.68 to $263.65). Read SEC document |
| April 21, 2020 Filed Apr 22, 2020 20:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 2,000 | $57.27 | $114,540.00 |
DisclosureSEC source: 0001209191-20-025342 · doc4.xml · nonDerivative · entry 6 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,875 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 20, 2020 Filed Apr 22, 2020 20:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $57.27 | $0.00 |
DisclosureSEC source: 0001209191-20-025342 · doc4.xml · derivative · entry 14 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,125 Underlying: Common Stock · 2,000 shares Expires 2022-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: Fully vested. Read SEC document |
| April 20, 2020 Filed Apr 22, 2020 20:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 500 | $274.65 | $137,325.00 |
DisclosureSEC source: 0001209191-20-025342 · doc4.xml · nonDerivative · entry 5 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,875 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $274.65 (range $274.37 to $275.32). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.